| Domain | Compact knowledge-base summary |
|---|---|
| Identity / identifiers | **Disease:** Loeys-Dietz syndrome type 2 (LDS2), the **TGFBR2-related** subtype of Loeys-Dietz syndrome; **MONDO:** `MONDO:0012427`; **Category:** Mendelian connective-tissue/aortopathy disorder; **Gene:** `TGFBR2` / ENSG00000163513; historical subtype nomenclature distinguishes LDS2 from broader LDS spectrum (pqac-00000000, pqac-00000003, pqac-00000006) |
| Cause / inheritance | **Primary cause:** heterozygous **germline pathogenic variants in TGFBR2**; inheritance is **autosomal dominant** with **variable expressivity** and reported nonpenetrance/de novo cases in broader LDS literature; **share of LDS due to TGFBR2:** **55–60%** (LDS2-specific within broad LDS) (pqac-00000003, pqac-00000004) |
| Hallmark phenotype | Core phenotype combines **aggressive arterial aneurysm/dissection**, **arterial tortuosity**, and craniofacial/skeletal connective-tissue findings such as **hypertelorism**, **bifid/broad uvula or cleft palate**, craniosynostosis, scoliosis, joint laxity/contractures; **aortic root aneurysm ~95%** is a **broad-LDS** figure, not LDS2-only; dissections can occur at **small diameters** and very young ages (broad LDS), including childhood (pqac-00000003, pqac-00000004, pqac-00000006, pqac-00000012) |
| Mechanism / pathophysiology | TGFBR2 encodes a **transmembrane serine/threonine kinase** in TGF-β signaling. Disease-causing variants are predominantly **missense variants in the kinase/STK domain**; functional studies show **reduced canonical SMAD2/3 signaling** in vitro, yet diseased aortic tissue shows **paradoxically increased pSMAD2** and activation of **noncanonical MAPK pathways (ERK1/2, p38)**. Key implicated cells/tissues: **vascular smooth muscle cells**, **adventitial fibroblasts**, extracellular matrix and elastin/contractile-unit architecture, with inflammatory infiltrates in models (pqac-00000014, pqac-00000015, pqac-00000016) |
| Diagnostics | Diagnosis is based on **clinical suspicion plus molecular confirmation of a TGFBR2 variant**; broad LDS clues include craniofacial findings plus diffuse arterial disease. Differential diagnosis includes **Marfan syndrome**, **vascular Ehlers-Danlos syndrome**, and other **heritable thoracic aortic diseases**. Gene-panel, WES, or WGS testing is useful because phenotypic overlap is substantial and VUS interpretation may require functional data (pqac-00000002, pqac-00000004, pqac-00000009) |
| Surveillance | **Echocardiography:** at least **annually**; more often if rapid progression. **Cross-sectional imaging (CTA/MRA):** **head-to-pelvis at diagnosis**, repeat at **1 year**, then every **2–3 years** unless abnormalities require closer follow-up. Children may also need **cervical spine flexion-extension radiographs every 3–5 years** when indicated (broad LDS management, applied to LDS2) (pqac-00000008, pqac-00000013) |
| Treatment / current care | Standard care is **blood-pressure reduction** and **prophylactic vascular surgery**. **ARBs** such as **losartan** are commonly used; cited target doses: **2.0 mg/kg/day in children** and **≥100 mg/day in adults**; **beta-blockers** may be combined. Activity advice: avoid **contact sports**, **isometric exertion**, and **exercise to exhaustion**. **Prophylactic aortic root surgery**: about **4.0 cm** in adults for **LDS1/LDS2** in expert management guidance; guideline/review thresholds across TGFBR1/TGFBR2 are approximately **4.2–4.5 cm (42–45 mm)**, individualized by sex, body size, family history, and syndromic severity (pqac-00000008, pqac-00000009, pqac-00000010) |
| Prognosis / outcomes | Major morbidity and mortality are **cardiovascular**, especially **aortic and extra-aortic dissections/rupture**; prognosis is improved by early diagnosis, surveillance, and prophylactic surgery, but risk persists after surgery because disease affects the full arterial tree. Pregnancy is high risk in broad LDS management literature: **arterial dissection 11%** and **uterine rupture 2%**, with highest risk in the perinatal/early postpartum period (broad LDS, not LDS2-only) (pqac-00000011, pqac-00000012, pqac-00000013) |
| Epidemiology | **Disease-specific prevalence/incidence for LDS2 are not established** in the gathered evidence. Broad rare-disease context applies. Within diagnosed LDS cohorts, **TGFBR2 accounts for 55–60%** of cases. A cited large broad-LDS cohort contained **441 patients from 228 families**, but this is not a population prevalence estimate (pqac-00000003, pqac-00000009) |
| Other clinically relevant manifestations | Broader LDS care literature reports increased risk of **allergic disease** (asthma, eczema, allergic rhinitis), **food allergy up to 30%**, and **eosinophilic GI disease or inflammatory bowel disease up to 60%**; **cervical spine instability ~50%** is also reported. These figures are **broad-LDS**, not proven LDS2-specific frequencies (pqac-00000011, pqac-00000013) |
| Evidence gaps | Key gaps include: lack of **LDS2-specific prevalence/incidence**, limited **variant-specific penetrance** estimates, sparse **LDS2-specific omics** and human tissue datasets, few controlled data proving superiority of **beta-blocker vs ARB vs combination therapy**, limited pregnancy outcome data stratified by **TGFBR2**, and reliance on **broad-LDS** rather than subtype-specific frequency estimates for many nonvascular manifestations (pqac-00000001, pqac-00000009, pqac-00000014, pqac-00000016) |


*Table: This table condenses the most clinically useful and ontology-relevant facts for Loeys-Dietz syndrome type 2, clearly distinguishing broad-LDS values from LDS2-specific evidence. It is useful as a quick curation aid for disease identity, management, and evidence gaps.*